NBRC Clinical Simulation Examination (CSE) Practice Exam

The primary purpose of using mucolytics in Cystic Fibrosis is to loosen and thin mucus. In Cystic Fibrosis, the production of thick and sticky mucus occurs due to a mutation in the CFTR gene, which leads to problems in chloride transport across epithelial cells. This thick mucus can obstruct airways, trap bacteria, and make it difficult for individuals to clear respiratory secretions.

Mucolytics are designed to decrease the viscosity of this mucus, improving its clearance from the airways. By thinning the mucus, mucolytics help patients expel secretions more easily, reducing the risk of lung infections and improving overall respiratory function. This management strategy is crucial for individuals with Cystic Fibrosis, as it directly addresses one of the hallmark symptoms of the disease.

While reducing inflammation, providing pain relief, or eliminating bacteria are important aspects of comprehensive care for Cystic Fibrosis, they are not the primary actions of mucolytics. These other options contribute to the overall management of the condition but do not specifically target the mucus clearance issue that mucolytics are designed to address.